Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition

被引:181
作者
Mager, DE [1 ]
Krzyzanski, W [1 ]
机构
[1] SUNY Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
基金
美国国家卫生研究院;
关键词
leukemia inhibitory factor; mathematical model; nonlinear pharmacokinetics; target-mediated drug disposition;
D O I
10.1007/s11095-005-6650-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose: The aim of this study is to derive and evaluate an equilibrium model of a previously developed general pharmacokinetic model for drugs exhibiting target-mediated drug disposition (TMDD). Methods: A quasi-equilibrium solution to the system of ordinary differential equations that describe the kinetics of TMDD was obtained. Computer simulations of the equilibrium model were carried out to generate plasma concentration-time profiles resulting from a large range of intravenous bolus doses. Additionally, the final model was fitted to previously published pharmacokinetic profiles of leukemia inhibitory factor (LIF), a cytokine that seems to exhibit TMDD, following intravenous administration of 12.5, 25, 100, 250, 500, or 750 mu g/kg in sheep. Results: Simulations show that pharmacokinetic profiles display steeper distribution phases for lower doses and similar terminal disposition phases, but with slight underestimation at early time points as theoretically expected. The final model well-described LIF pharmacokinetics, and the final parameters, which were estimated with relatively good precision, were in good agreement with literature values. Conclusions: An equilibrium model of TMDD is developed that recapitulates the essential features of the full general model and eliminates the need for estimating drug-binding microconstants that are often difficult or impossible to identify from typical in vivo pharmacokinetic data.
引用
收藏
页码:1589 / 1596
页数:8
相关论文
共 20 条
[1]  
D'Argenio DZ, 1997, ADAPT 2 USERS GUIDE
[2]   Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives [J].
Derendorf, H ;
Meibohm, B .
PHARMACEUTICAL RESEARCH, 1999, 16 (02) :176-185
[3]   A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans [J].
Eppler, SM ;
Combs, DL ;
Henry, TD ;
Lopez, JJ ;
Ellis, SG ;
Yi, JH ;
Annex, BH ;
McCluskey, ER ;
Zioncheck, TF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (01) :20-32
[4]  
Gibaldi M, 1982, Pharmacokinetics, V15
[5]   Pharmacokinetic model of target-mediated disposition of thrombopoietin [J].
Jin F. ;
Krzyzanski W. .
AAPS PharmSci, 6 (1)
[6]   Endothelial binding of recombinant tissue plasminogen activator:: Quantification in vivo using a recirculatory model [J].
Kemme, MJB ;
Schoemaker, RC ;
Burggraaf, J ;
van der Linden, M ;
Noordzij, M ;
Moerland, M ;
Kluft, C ;
Cohen, AF .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2003, 30 (01) :3-22
[7]   PHARMACOLOGICAL TARGET-MEDIATED DRUG DISPOSITION [J].
LEVY, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (03) :248-252
[8]   Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man [J].
Levy, G ;
Mager, DE ;
Cheung, WK ;
Jusko, W .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (05) :985-994
[9]  
Lin C.C., 1974, MATH APPL DETERMINIS
[10]   Antibody pharmacokinetics and pharmacodynamics [J].
Lobo, ED ;
Hansen, RJ ;
Balthasar, JP .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (11) :2645-2668